{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:50:12Z","timestamp":1762505412486},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,10,28]],"date-time":"2008-10-28T00:00:00Z","timestamp":1225152000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1038\/ncponc1262","type":"journal-article","created":{"date-parts":[[2008,10,28]],"date-time":"2008-10-28T13:05:50Z","timestamp":1225199150000},"page":"12-13","source":"Crossref","is-referenced-by-count":9,"title":["Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?"],"prefix":"10.1038","volume":"6","author":[{"given":"Emmanuel S","family":"Antonarakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario A","family":"Eisenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,28]]},"reference":[{"key":"BFncponc1262_CR1","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","volume":"26","author":"G Attard","year":"2008","unstructured":"Attard G  et al. (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26: 4563\u20134571","journal-title":"J Clin Oncol"},{"key":"BFncponc1262_CR2","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.1158\/0008-5472.CAN-06-3332","volume":"67","author":"EA Mostaghel","year":"2007","unstructured":"Mostaghel EA  et al. (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67: 5033\u20135041","journal-title":"Cancer Res"},{"key":"BFncponc1262_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1677\/JOE-07-0131","volume":"194","author":"A Stigliano","year":"2007","unstructured":"Stigliano A  et al. (2007) Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer. J Endocrinol 194: 55\u201361","journal-title":"J Endocrinol"},{"key":"BFncponc1262_CR4","doi-asserted-by":"publisher","first-page":"8242","DOI":"10.1200\/JCO.2005.03.3092","volume":"23","author":"CJ Ryan","year":"2005","unstructured":"Ryan CJ and Eisenberger MA (2005) Chemotherapy for hormone-refractory prostate cancer: now it's a question of \u201cwhen?\u201d J Clin Oncol 23: 8242\u20138246","journal-title":"J Clin Oncol"},{"key":"BFncponc1262_CR5","doi-asserted-by":"publisher","first-page":"5018","DOI":"10.1200\/jco.2008.26.15_suppl.5018","volume":"26","author":"CJ Ryan","year":"2008","unstructured":"Ryan CJ  et al. (2008) Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17\u03b1-hydroxylase C17,20-lyase inhibitor, in castration-resistant prostate cancer (CRPC) [abstract]. J Clin Oncol 26: 5018","journal-title":"J Clin Oncol"},{"key":"BFncponc1262_CR6","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/jco.2008.26.15_suppl.5005","volume":"26","author":"JS De Bono","year":"2008","unstructured":"De Bono JS  et al. (2008) Antitumor activity of abiraterone acetate, a CYP17 inhibitor of androgen synthesis, in chemotherapy-naive and docetaxel pretreated castration-resistant prostate cancer (CRPC) [abstract]. J Clin Oncol 26: 5005","journal-title":"J Clin Oncol"},{"key":"BFncponc1262_CR7","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1200\/jco.2008.26.15_suppl.5019","volume":"26","author":"DC Danila","year":"2008","unstructured":"Danila DC  et al. (2008) Abiraterone acetate and prednisone in patients with progressive metastatic castration-resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy [abstract]. J Clin Oncol 26: 5019","journal-title":"J Clin Oncol"}],"container-title":["Nature Clinical Practice Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncponc1262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc1262","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/ncponc1262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/ncponc1262.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:54:20Z","timestamp":1684443260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncponc1262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,28]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["BFncponc1262"],"URL":"https:\/\/doi.org\/10.1038\/ncponc1262","relation":{},"ISSN":["1743-4254","1743-4262"],"issn-type":[{"value":"1743-4254","type":"print"},{"value":"1743-4262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,28]]}}}